MSCI Maintains Korea's Emerging Market Status in Latest Review
MSCI Inc. has decided to keep South Korea in its emerging-market index, deferring a potential upgrade to developed-market status due to unresolved market accessibility issues. Despite measures taken by Korean authorities, MSCI noted that the Korean won's onshore liquidity for extended FX trading hours remains insufficient, hindering operational flexibility for index replicators. While the South Korean government anticipates eventual inclusion through continued reforms, analysts predict it may take until 2027 to join the watch list and 2029 for full developed-market entry.
uniQure prices $225M public offering at $45.50 per share By Investing.com
uniQure N.V. (NASDAQ:QURE) announced it priced an underwritten public offering of 4,945,055 ordinary shares at $45.50 per share, aiming to generate approximately $225 million in gross proceeds. The gene therapy company also granted underwriters a 30-day option to purchase additional shares and expects the offering to close around June 25, 2026. Despite a 245% stock surge and a market cap of $3.09 billion, InvestingPro analysis suggests the company is overvalued and remains unprofitable with an EPS of -$3.49.
Japan Post Holdings sells $3.25m Aflac (NYSE:AFL) stock By Investing.com
Japan Post Holdings, a 10% owner of Aflac Inc., sold approximately $3.25 million worth of Aflac common stock on June 22, 2026. The sales involved two separate transactions at weighted average prices of $116.57 and $117.46 per share, respectively. Following these sales, Japan Post Holdings indirectly retains beneficial ownership of over 50 million Aflac shares.
Conagra Brands director Emanuel Chirico to step down after current term
Conagra Brands announced that director Emanuel Chirico will not seek re-election at the 2026 Annual Meeting of Shareholders but will complete his current term. This decision is not due to any disagreement with the board. The company's stock is currently trading down 32% over the past year but is considered undervalued by InvestingPro analysis, maintaining a 10.4% dividend yield and a 51-year dividend payment streak.
Take-Two director Jon Moses sells $122,305 in company stock
Jon J. Moses, a director at Take-Two Interactive Software Inc., sold 500 shares of company stock for $122,305 on June 22, 2026. This transaction leaves him with 21,868 directly held shares. The sale occurred while the stock was trading near its 52-week high, and InvestingPro analysis suggests the company might be overvalued, although analysts predict profitability this year.
The Ball Aluminum Cup from Ball Corp. - reusable feel for cold drinks
Ball Corporation's Aluminum Cup offers a reusable and recyclable alternative to plastic for cold beverages, known for its cold metallic feel and durability. Primarily targeting stadiums, bars, and events, it also comes in retail packs for home use, aligning with Ball Corp.'s sustainability focus on aluminum packaging. While more expensive than plastic, its premium feel and recyclability appeal to consumers and venues seeking eco-friendlier options.
Form 4 Liveramp Holdings Inc For: 23 June By Investing.com
This article is a brief financial update indicating the filing of a Form 4 for Liveramp Holdings Inc on June 23. It includes a trading symbol for Liveramp Holdings (RAMP) and briefly highlights its stock performance (-0.03%). The content is very short and serves primarily as a notification.
June 29, 2026 Deadline: Join Class Action Lawsuit Against POET Technologies Inc. (POET) - Contact Levi & Korsinsky
Levi & Korsinsky, LLP has filed a securities class action lawsuit against POET Technologies Inc. (NASDAQ:POET) on behalf of investors who suffered losses between April 1, 2026, and April 27, 2026. The lawsuit alleges that POET Technologies made false statements concerning its tax status as a potential passive foreign investment company and a violation of a non-disclosure agreement by a defendant. Investors are encouraged to contact Levi & Korsinsky by the June 29, 2026 deadline to explore potential recovery.
QURE Stock Soars As FDA Backs Accelerated Huntington’s Therapy Path
uniQure N.V. (QURE) stock has seen a significant surge after the FDA indicated that three-year Phase I/II data for its AMT-130 gene therapy could support an accelerated approval pathway for Huntington’s disease. This regulatory clarity has led to a re-rating of the stock, with major banks raising price targets and upgrading their recommendations. Despite high financial risk metrics typical of biotech, QURE's balance sheet provides runway, making it a high-momentum regulatory play for traders.
Riskified director Shachar Erez sells $870,811 in shares By Investing.com
Shachar Erez, a director at Riskified (NASDAQ:RSKD), recently sold Class A Ordinary Shares worth $870,811 through Qumra Capital entities. These sales, conducted on June 18 and June 22, 2026, were part of a Rule 10b5-1 trading plan and involved 176,804 shares at prices between $4.85 and $5.00. The transactions occurred while the stock was near its 52-week low, and follow other company news including a new share repurchase authorization and mixed Q1 2026 earnings.